Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Express clothing and Coca Cola bought more.
$POZN nice gains since the matrix alert! Alerted when this was about to come out of stagnant sideways move. Been rockin it! Sign up for matrix alerts http://www.matrixpennystocks.com
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93132396
Psdv 5.23 moving ahead looking solid.
ATRS $4.02 stock chart shows Golden cross (bullish) and took a breather toward the 'magic' 200ma giving us a great opportunity on wednesday and thursday, maybe friday too. Weekly chart (2nd chart below), shows it is now sitting near the lower bollinger bands and sitting at the trend-line spanning back to beginning to 2012.
BLRX got some today. Will be adding more in the coming days. Nice set up here with bullish trend.
DCTH could be a great bottom play at .3s!
MATRIX GIVES 20% referral fee for new ad leads at our nornal rate!!!
PSDV $3.83 this is highly likely to be fda approved. IMO, it's a Better play than ALIM since ALIM has to pay 25mil milestone payment to PSDV upon approval. Chart is also in pattern break out mode
AEZS in $1.38 sold $1.70 for another successful trade! May get back in later. Sign up http://www.matrixpennystocks.com
APPY up 13% since alert! SIGN UP http://matrixpennystocks.com
AEZS up more than 20% since alert! SIGN UP http://matrixpennystocks.com
Hello bartender, ill have some Psdv on the rocks.
AMD sideways move the past few days coming close to an end imo. New APU chip coming and looks like they are on schedule too.
Fnma accumulating here and holding long
Aezs on the move
EGOC something huge going on
FCGD smells like accumulation!!!!!!!!!!!!!!!!!!
No catching up with FCGD when she runs
$DRRX rockin it today since the alert! sign up http://www.matrixpennystocks.com
APPA up nicely since the realert!
Sign up for alerts http://www.matrixpennystocks.com
AMRN also up 6%. $5.60 But looking at the weekly chart, it is wise to start thinking of taking some profit while you still can.
http://stockcharts.com/c-sc/sc?chart=amrn,uu[e,a]whclyiay[wc][pb5!b10!b50!b200!d20,2!f!e][vc5!c20][iut!la!le12,26,9!ll14!lk9!lb2!lb5!lb14!lh!li!lp5,5!lv8!uc15!ld14!lya7,14,28!lo20!ls!lf!lg!lj!ln!lq!lm!lad!lac!lr!lt!ut!uu][j204449,y]&r=3555%3Cbr
PSDV up nicely since alert. sign up at http://matrixpennystocks.com
PSDV got back in for a nice bounce play. Multiple products are in line with excellent results. $25 million mile stone payment upon approval of iluvien in october!
Sign Up For Alerts
http://www.matrixpennystocks.com
AMRN DD : Key events october 16 & December 20...
and some articles
http://seekingalpha.com/article/1538972-analysis-of-amarin-s-offering-and-vascepa-update?source=email_rt_mc_focus_0
http://seekingalpha.com/article/1533642-cover-your-amarin-short-and-go-long?source=email_rt_mc_focus_2
http://seekingalpha.com/article/1513802-2-big-name-biopharma-catalysts-for-second-half-2013?source=email_rt_mc_related_1
POZN Closing in on 200 MA looking strong if it breaks will be clear skies
POZN up almost 10% since alert. fundamentals support the move. holding for now
Sign up for alerts http://matrixpennystocks.com
ONCS good entry here, gonna see a nice bounce off these levels. News came out this morning too.
OncoSec Medical Announces Completion of Enrollment of Phase II Metastatic Melanoma Trial
Jun 18, 2013 06:05:00 (ET)
SAN DIEGO, Jun 18, 2013 (BUSINESS WIRE) -- OncoSec Medical Inc. (otcqb:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced the completion of patient enrollment in a Phase II clinical trial of ImmunoPulse for metastatic melanoma patients.
The Phase II trial is evaluating efficacy of ImmunoPulse in subjects with Stage IIIb to IVa in-transit cutaneous metastatic melanoma with a primary endpoint of overall objective response (OOR) at 6 months as measured by modified RECIST. Secondary endpoints for this study will evaluate safety and tolerability, as well as local response of treated lesions at Day 90.
"We are pleased that our development milestones continue to meet our expectations. We have shown great adoption of ImmunoPulse with the clinical centers enrolling in this Phase II clinical trial for advanced-stage melanoma patients," said Punit Dhillon, President and CEO of OncoSec Medical. "We are now interested in directing the focus to data analysis and the design of our next studies for the melanoma program, including expanding the adoption across other key centers of excellence."
The ImmunoPulse trial is a single-arm, open-label and multicenter study. The trial is designed to assess local and distant response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety. This multicenter trial is being conducted in the United States at the University of California San Francisco, the University of Washington and the John Wayne Cancer Institute.
Previously, OncoSec provided an interim safety analysis of 13 patients of its Phase II metastatic melanoma program. The results showed that 95 percent of evaluable treated lesions demonstrated a response at Day 39 and Day 90. In addition, two subjects who were evaluable for the primary endpoint of overall objective response at Day 180 both demonstrated a clinically relevant objective response as measured by RECIST. In March 2013, an update of interim data was announced demonstrating durability of response of treated lesions. These data showed that all melanoma lesions that demonstrated at least a partial or complete response to treatment with ImmunoPulse had a 68 percent and 45 percent durable response at three and six months, respectively.
About ImmunoPulse
ImmunoPulse utilizes the DNA plasmid interleukin-12 (IL-12), which is injected directly into the tumor. After the injection, six needle-like electrodes hooked up to a generator are inserted into the skin around the tumor. Short pulses of 1,300 volts are then administered, and the electric field causes the pores of the cancer cells' membranes to temporarily open, allowing the DNA plasmid to enter directly into the open pores. Upon entry, the gene triggers each cell to produce and secrete the IL-12 protein, which in turn identifies and eliminates cancerous cells as part of a natural immune response.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/ .
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130618005573r1&sid=cmtx6&distro=nx
SOURCE: OncoSec Medical Inc.
Investor Relations:
OncoSec Medical Inc.
Amy Chan
855-662-6732
investors@oncosec.com
or
Public Relations:
Dian Griesel Inc.
Laura Radocaj
212-825-3210
lradocaj@dgicomm.com
Regarding ALIM's product ILUVIEN
ILUVIEN (190 micrograms intravitreal implant in applicator) is a sustained release intravitreal implant used to treat vision impairment associated with chronic DME considered insufficiently responsive to available therapies. Each ILUVIEN implant provides a therapeutic effect of up to 36 months by delivering sustained sub-microgram levels of fluocinolone acetonide (FAc). ILUVIEN is injected in the back of the patient's eye to a position that takes advantage of the eye's natural fluid dynamics. The applicator employs a 25-gauge needle, which allows for a self-sealing wound.
In July 2010, Alimera submitted a Marketing Authorization Application (MAA) to seven European countries via the Decentralized Procedure (DCP) with the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA) serving as the Reference Member State (RMS). The MAA included data from two Phase 3 pivotal clinical trials (collectively known as the FAME(TM) Study) for ILUVIEN conducted by Alimera. The trials involved 956 patients in sites across the United States, Canada, Europe and India to assess the efficacy and safety of ILUVIEN for the treatment of DME. At the end of the DCP, a consensus was reached by the RMS and the other six countries that the MAA for ILUVIEN was approvable. To date, six of the seven countries, Austria, the United Kingdom, Portugal, France, Spain and Germany have granted national licenses for ILUVIEN. ILUVIEN has not been approved by the United States Food and Drug Administration.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.
ALIM / PSDV treatment of DME chronic diabetic macular edema is on wikipedia too as an approved treatment in several countries.
http://en.wikipedia.org/wiki/Macular_edema
Iluvien, a sustained release intravitreal implant developed by Alimera Sciences, has been approved in Austria, Portugal and the U.K. for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Additional EU country approvals are anticipated.[3]
((( Matrix is On Fire!! SIGN UP FOR ALERTS )))
ALIM up 56% since board alert. PSDV up 22% and climbing. Solid plays.
Sign Up For Alerts http://matrixpennystocks.com
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87865161
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87868692
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87870412
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=88360579
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87900046
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=88151626
ALIM / PSDV high alert... strong plays solid fundamentals.
ALIM up 55% since board alert (other board) last month or so
onci lookin goooooo
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
59
|
Created
|
05/31/13
|
Type
|
Premium
|
Moderator Psionic Trader | |||
Assistants |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |